Hepatitis A vaccines: the growing case for universal immunisation of children.
Hepatitis A virus (HAV) infection results in a debilitating, multi-week illness in older children and adults that can be avoided with pre-exposure immunisation. Inactivated HAV vaccines are safe, highly effective and induce long-lasting protection. Immunisation has typically been recommended only for groups at highest risk of infection or complications, with variable success. This paper reviews the outcomes of several new programmes of universal HAV immunisation of children and/or adolescents. These programmes were associated with substantial disease rate reductions, extending beyond the immunised individuals and age groups (herd immunity), and promise additional benefits as immunised cohorts enter adulthood risk groups. Universal programmes are cost-effective, especially when a combined hepatitis A and B vaccine can be used to minimise incremental costs, and deserve wider consideration in developed countries.
Scheifele
David W
DW
BC Children's Hospital, Vaccine Evaluation Center, University of British Columbia, Vancouver, British Columbia, Canada. dscheifele@cw.bc.ca
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006506:Hepatitis A / Q000453:epidemiology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000627:therapeutic use*; D006801:Humans; D007114:Immunization / Q000379:methods* / Q000706:statistics & numerical data; D017589:Immunization Programs / Q000379:methods* / Q000706:statistics & numerical data
D022362:Hepatitis A Vaccines